News Jounce elopes with Concentra, leaving Redx at the altar A $425 million proposed marriage between Redx Pharma of the UK and Jounce Ther
News Concentra gatecrashes Jounce and Redx’ merger party Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
R&D The Alderley Park Discovery Podcast: The journey to accessin... Episode 3 of the Alderley Park Discovery Podcast covers how to successfully access life science funding and investment, highlighting a range of ways companies can attract investors.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
